Target intelligence / Profile preview

NUF2 component of NDC80 kinetochore complex (NUF2)

Target
NUF2
Molecular classification
Kinetochore protein, Structural complex component, Other (heterotetrameric protein complex)
01

Overview

NUF2 is a **core component of the NDC80 kinetochore complex**, a heterotetramer consisting of NUF2, NDC80 (also known as Hec1), SPC24, and SPC25[1][6]. This complex is **essential for the physical connection between spindle microtubules and centromeric chromosomal DNA during mitosis**[2][3][6]. The NUF2 subunit, together with NDC80, forms a microtubule-binding module localized at kinetochores that ensures proper chromosome alignment, spindle checkpoint signaling, and the equal segregation of chromosomes to daughter cells[3][6][7]. Recent studies have broadened its known functions to include a regulatory role in **ribosome biogenesis** during interphase, linking kinetochore machinery to nucleolar activity and cellular protein synthesis[1]. Aberrant NUF2/NDC80 activity can result in chromosomal instability, a hallmark of cancer, making it a potential therapeutic target for anti-mitotic agents, though no approved drugs directly target this complex as of now[1].

Other names
NUF2Nuf2pNuclear filamentous 2
02

Mechanism of action

Not applicable for approved drugs; pharmacological mechanism would hypothetically involve disruption of kinetochore-microtubule attachment, leading to mitotic arrest and cell death (as targeted by experimental tool compounds or investigational agents in research)

03

Biological functions

Chromosome segregationCell division (mitosis)Kinetochore-microtubule attachmentRegulation of cell cycle checkpointRibosome biogenesis (recently discovered non-canonical function)
04

Disease associations

Cancer (due to its critical role in mitosis and chromosome segregation errors associated with tumorigenesis)Other (potentially cell cycle/arrest pathways)
05

Safety considerations

Inhibiting NUF2/NDC80 complex function would be expected to induce mitotic arrest and apoptosis broadly in dividing cells, leading to potential for toxicity in proliferative tissues (hematopoietic, gut, hair, etc.).
06

Interacting drugs

None known as established, direct small-molecule drugs. There is no evidence in results of approved or clinical-stage drugs directly inhibiting or modulating NUF2 or the NDC80 complex.
07

Biomarkers

Elevated expression of NUF2 is under investigation as a proliferation marker in cancer studies. No clinically approved patient selection or efficacy biomarkers referenced in search results.

Beyond the preview

Go deeper on NUF2 component of NDC80 kinetochore complex (NUF2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUF2 component of NDC80 kinetochore complex (NUF2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call